YUNNAN BAIYAO(SZ:000538)2024-12-13 10:02Financial Performance - In the first three quarters of 2024, the company achieved a revenue of 29.915 billion yuan, a year-on-year increase of 0.76% [2] - The net profit attributable to shareholders was 4.327 billion yuan, up 4.93% year-on-year [2] - The basic earnings per share reached 2.42 yuan, reflecting a growth of 4.76% [2] - The net cash flow from operating activities was 4.073 billion yuan, a significant increase of 57.29% [2] - The weighted average return on equity was 10.82%, an increase of 0.34 percentage points year-on-year [2] Pharmaceutical Business Growth - The pharmaceutical segment focused on core products and implemented measures in clinical research, marketing, and production efficiency [3] - The marketing campaign included a basketball event with over 512 teams participating, generating over 2.9 billion views on Douyin [4] - Online channel expansion resulted in approximately 3.5 billion exposures and 2.96 million interactions, with 1.052 million visitors driven to e-commerce platforms [4] - The gross merchandise volume (GMV) increased by 47% year-on-year [4] R&D Progress - The company received approval for clinical trials of the Fluorobiphenyl Gel, aimed at pain relief and anti-inflammatory effects [5] - Other products, such as the Loxoprofen Sodium Gel, have completed pilot tests and initial research on adhesive performance [5] Health Products Performance - The toothpaste market share remained leading, with the brand ranking first in oral care during the 2024 "618" shopping festival [7] - The sales revenue for hair care products reached 195 million yuan, with a growth rate of 41% [7] Traditional Chinese Medicine Initiatives - The company aims to leverage Yunnan's medicinal resources to enhance the traditional Chinese medicine industry [8] - A digital platform for the traditional Chinese medicine industry was launched to improve transaction efficiency and transparency [9][10] - The company plans to strengthen the entire industry chain of the medicinal herb "Sanqi" [10] Dividend Policy - In 2023, the company distributed a cash dividend of 20.77 yuan per 10 shares, totaling 3.706 billion yuan, which accounted for 90.53% of the net profit [11] - A special dividend of 12.13 yuan per 10 shares is planned for 2024, amounting to 2.164 billion yuan, representing 50.02% of the net profit for the first three quarters of 2024 [11] - The company has consistently paid dividends for 31 years, with total cash dividends exceeding 26.6 billion yuan [11]